AARDEX Group Joins IT4Anxiety Project
AARDEX Group joins the IT4Anxiety Project [https://www.nweurope.eu/projects/project-search/it4anxiety-managing-anxiety-via-innovative-technologies-for-better-mental-health/] to support the implementation of innovative solutions to reduce anxiety of those living with neurodegenerative diseases or post-traumatic stress disorder (PTSD). AARDEX Group will enroll their tools and solutions that they used in clinical trials in this study to monitor medication adherence in daily clinical practice. Older adults living with dementia are impacted by non-adherence to medications. AARDEX Group will be able to observe how people interact with the solution to then be individualized for future service users. Vincoane de Moffarts, IT4Anxiety lead partner, commented that theseco-created innovative solutions will aim to be implemented to address the needs of this population.
Read more about this news release here.
New machine-learning approach could speed precision drug development
The approach, detailed this week in the journal Nature, uses a platform called Molecular Surface Interaction Fingerprinting (MaSIF) to design custom proteins that bind to drug-bound target proteins.
AI-enabled CGM app shows promise for glycemic control, weight management
The broader implications of this study suggest that digital health platforms like January V2 have the potential to play a crucial role in the future of chronic disease management,” the authors write.
